Showing results (1331-1340 of 1,365) with videos related to

Sort By:
Pageof 137
Kidney International Supplements|May 13, 2021
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in AfricaFidelis Oguejiofor, Daniel S Kiggundu, Aminu K Bello, et al.
Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.
Therapeutic Advances in Medical Oncology|August 7, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysisQiaofeng Zhong, Longfeng Zhang, Lin Wu, et al.
Kidney International Supplements|April 15, 2024
Capacity for the management of kidney failure in the International Society of Nephrology Africa region: report from the 2023 ISN Global Kidney Atlas (ISN-GKHA)Elliot Koranteng Tannor, Bianca Davidson, Yannick Nlandu, et al.
Nature Communications|October 27, 2023
Gut microbiota impacts bone via Bacteroides vulgatus-valeric acid-related pathwaysXu Lin, Hong-Mei Xiao, Hui-Min Liu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 16, 2020
Availability, Accessibility, and Quality of Conservative Kidney Management WorldwideMeaghan Lunney, Aminu K Bello, Adeera Levin, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Jie Huang, Tao Wang, et al.
The Journal of Clinical Investigation|July 8, 2020
Kinetics of viral load and antibody response in relation to COVID-19 severityYanqun Wang, Lu Zhang, Ling Sang, et al.
Cancer Communications (London, England)|February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II studyJing Zheng, Tao Wang, Yunpeng Yang, et al.
Pageof 137